水解婴儿配方奶粉与常规配方奶粉对1型糖尿病风险的影响:TRIGR随机临床试验
TRIGR国际双盲随机临床试验纳入2159名具有遗传易感性且一级亲属患1型糖尿病的婴儿,比较断奶后使用深度水解酪蛋白配方与常规配方对1型糖尿病累积发病率的影响。
要点
- 在1型糖尿病高危婴儿中,断奶后使用深度水解酪蛋白配方并未降低1型糖尿病的累积发病率。
- 中位随访11.5年,水解配方组1型糖尿病绝对风险8.4% vs 常规配方组7.6%,差异无统计学意义。
- 这些发现不支持修改针对1型糖尿病高危婴儿的膳食建议。
核心结论
- 在具有1型糖尿病风险的婴儿中,与常规配方相比,断奶后使用水解配方并未降低中位随访11.5年后的1型糖尿病累积发病率。
- 这些发现不支持需要修改针对1型糖尿病风险婴儿的膳食建议。
研究设计与样本
- 国际双盲随机临床试验,2002年5月至2007年1月从15个国家78个研究中心招募2159名具有人类白细胞抗原(HLA) conferring疾病易感性且一级亲属患1型糖尿病的婴儿。
- 1081名随机分配至断奶后使用深度水解酪蛋白配方,1078名分配至常规配方;研究配方暴露最短持续时间为60天,至6-8月龄;参与者随访于2017年2月28日结束。
主要发现
- 2159名新生儿(1021名女性[47.3%])中1744名(80.8%)完成试验,中位观察11.5年(四分位距Q1-Q3,10.2-12.8)。
- 随机分配至酪蛋白水解物组的1型糖尿病绝对风险为8.4%(n=91),常规配方组为7.6%(n=82),差异0.8%(95%CI,-1.6%至3.2%)。
- 两组1型糖尿病诊断中位年龄相似(6.0岁[Q1-Q3,3.1-8.9] vs 5.8岁[Q1-Q3,2.6-9.1];差异0.2岁[95%CI,-0.9至1.2])。
- 上呼吸道感染是最常见的不良事件(水解物组年发生频率0.48次,对照组0.50次)。
关键数值与推荐
- 主要结局为根据世界卫生组织(WHO)标准诊断的1型糖尿病;次要结局包括诊断年龄和安全性(不良事件)。
临床怎么用
- 对于1型糖尿病高危婴儿,断奶后使用深度水解配方与常规配方相比未显示降低1型糖尿病累积发病率,这些发现不支持修改现有膳食建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE: To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS: An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. INTERVENTIONS: The participants received either a casein hydrolysate or a conventional adapted cow's milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. MAIN OUTCOMES AND MEASURES: Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS: Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (n = 91) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8% [95% CI, -1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE: Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00179777.
引用
- Knip M, Åkerblom HK, Al Taji E, et al. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial. JAMA. 2018. PMID: 29297078. doi:10.1001/jama.2017.19826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。